# Barramundi Group

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/barramundi-group

- Industry: Agribusiness
- Headquarters: Singapore, Singapore
- Website: www.barramundi.com
- Total disclosed funding: $50M
- Latest round: Series C (Mar 13, 2020)
- Investors on record: 8

## About

Based in Singapore, and founded in 2008, Barramundi Group, f.k.a. Barramundi Asia Pte. Ltd., a.k.a. Barramundi Group operates as a producer of barramundi fish through an integrated, full-spectrum aquaculture model, allowing to manage fish’s life and product cycles. The company operates barramundi farms in Australasia as well as distributes its products through Cone Bay Barra, Fassler Gourmet, and Kuhlbarra brands across Singapore, Australia, Korea, China, Hong Kong, the US, and more. As of May 2022, Andreas von Scholten is the CEO of Barramundi Group Ltd. In August 2021, Barramundi Group raised NOK 130.8 million in an IPO, selling 8.9 million shares at NOK 14.70 per share on the Euronext Growth Oslo under the ticker symbol "BARRA".

Barramundi Group provides barramundi, a premium white fish that is a vital source of protein. The company produces barramundi through the breeding process, from broodstock to hatchery, and safeguarding aquaculture through autogenous vaccines and animal health monitoring. The firm’s client base includes about 1,600 restaurants, hotels, and retailers in selected markets.

## Funding rounds

- Series C, Mar 13, 2020, $40M — Southern Capital Group, Louis Dreyfus Company B.V., FHJ International, Temasek Life Sciences Accelerator, Crista
- Series A, Jun 10, 2016, $10M — Crista, Barramundi Group, Stahl Capital, Optinator.se

## Investors

- Crista — Series A, Series C
- Barramundi Group — Series A
- Stahl Capital (https://capitalatlas.ai/funds/stahl-capital) — Series A
- Optinator.se — Series A
- Southern Capital Group (https://capitalatlas.ai/funds/southern-capital-group) — Series C
- Louis Dreyfus Company B.V. — Series C
- FHJ International — Series C
- Temasek Life Sciences Accelerator (https://capitalatlas.ai/funds/temasek-life-sciences-accelerator) — Series C